SEC Comment Letter 0000000000-24-012726 to enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc.
Date: Nov. 18, 2024 · CIK: 0001980845 · Accession: 0000000000-24-012726
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283201
Letter
November 18, 2024 Ronald H. W. Cooper Chief Executive Officer enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R 2P1 Re:enGene Holdings Inc. Registration Statement on Form S-3 Filed November 13, 2024 File No. 333-283201 Dear Ronald H. W. Cooper: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Julio E. Vega, Esq.
Show Raw Text
November 18, 2024
Ronald H. W. Cooper
Chief Executive Officer
enGene Holdings Inc.
4868 Rue Levy, Suite 220
Saint-Laurent, QC H4R 2P1
Re:enGene Holdings Inc.
Registration Statement on Form S-3
Filed November 13, 2024
File No. 333-283201
Dear Ronald H. W. Cooper:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Julio E. Vega, Esq.